Israel - English - Ministry of Health

rafa laboratories ltd - pyridostigmine bromide - tablets - pyridostigmine bromide 30 mg - pyridostigmine - pyridostigmine - pyridostigmine belongs to the cholinesterase inhibitor group and is indicated for the treatment of myasthenia gravis.

Israel - English - Ministry of Health

rafa laboratories ltd - pyridostigmine bromide - tablets - pyridostigmine bromide 60 mg - pyridostigmine - pyridostigmine - pyridostigmine belons to the cholinesterase inhibitor group and is indicated for the treatment of myasthenia gravis.

United States - English - NLM (National Library of Medicine)

bausch health us, llc - pyridostigmine bromide (unii: kvi301na53) (pyridostigmine - unii:19qm69hh21) - pyridostigmine bromide 60 mg in 5 ml - mestinon is contraindicated in mechanical intestinal or urinary obstruction, and particular caution should be used in its administration to patients with bronchial asthma. care should be observed in the use of atropine for counteracting side effects, as discussed below.

United States - English - NLM (National Library of Medicine)

sandoz inc - pyridostigmine bromide (unii: kvi301na53) (pyridostigmine - unii:19qm69hh21) - pyridostigmine bromide 5 mg in 1 ml - regonol ® (pyridostigmine bromide injection, usp) is indicated as a reversal agent or antagonist to the neuromuscular blocking effects of nondepolarizing muscle relaxants. known hypersensitivity to anticholinesterase agents; intestinal and urinary obstructions of mechanical type.

United States - English - NLM (National Library of Medicine)

surgeon general-department of the army (tsg-da) - pyridostigmine bromide (unii: kvi301na53) (pyridostigmine - unii:19qm69hh21) - pyridostigmine bromide is indicated for pretreatment against the lethal effects of soman nerve agent poisoning. pyridostigmine bromide is intended for use in conjunction with protective garments, including a mask. at the first sign of nerve agent poisoning, pyridostigmine bromide should be stopped, and atropine and pralidoxime therapy started immediately. the evidence for the effectiveness of pyridostigmine bromide as pretreatment against soman-induced toxicity was derived from animal studies alone. [see nonclinical toxicology (13.2) .] for military medical use only - mechanical intestinal or urinary obstruction - known hypersensitivity to anticholinesterase agents pregnancy category b pyridostigmine bromide produced no teratogenic effects in rats given up to 30 mg/kg/day and in rabbits given up to 45 mg/kg/day orally during the period of organogenesis. these doses are 3 and 10 times, respectively, the recommended human dose of 90 mg on an mg/m2 basis. in rats, a slight degree of delayed skeletal ossification was seen at 30 mg/kg, a dose which caused maternal toxicity, and a slight increase in the incidence of hydronephrosis was seen at all dose levels (lowest dose tested was 3 mg/kg). in rabbits, a slight increase in the incidence of hydronephrosis was seen at 45 mg/kg, a dose that caused maternal toxicity and increased incidences of blood vessel variations were seen at all doses (lowest dose tested was 5 mg/kg). there are no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when pyridostigmine bromide is administered to a nursing woman. safety and effectiveness in pediatric patients have not been established. clinical studies of pyridostigmine bromide did not contain sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. in general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. in the elderly (71 to 85 years of age) the elimination half-life, volume of distribution (central and steady state) were comparable with the young (21to 51 years of age). however, the systemic plasma clearance was significantly lower in the elderly compared to the young (6.7 ± 2.2 vs. 9.5 ± 2.7 ml/min/kg). this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. caution should be observed, and dosage be selected carefully, when administering pyridostigmine bromide to patients with impaired renal function. in anephric patients, a 3-fold increase in the elimination half-life and a 75% decrease in systemic clearance were observed. [see clinical pharmacology (12.3).] it may be useful to monitor renal function. no information is available on the pharmacokinetics of pyridostigmine bromide in hepatic impaired patients. although the abuse potential of pyridostigmine bromide has not been specifically assessed, no abuse of, tolerance to, withdrawal from, or drug-seeking behavior was observed in patients who received pyridostigmine bromide in clinical trials. cholinesterase inhibitors are not believed to be associated with drug abuse.

United States - English - NLM (National Library of Medicine)

avpak - pyridostigmine bromide (unii: kvi301na53) (pyridostigmine - unii:19qm69hh21) - pyridostigmine bromide tablets are useful in the treatment of myasthenia gravis. pyridostigmine bromide tablets are contraindicated in mechanical intestinal or urinary obstruction, and particular caution should be used in its administration to patients with bronchial asthma. care should be observed in the use of atropine for counteracting side effects, as discussed below.

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - pyridostigmine bromide (unii: kvi301na53) (pyridostigmine - unii:19qm69hh21) - pyridostigmine bromide is useful in the treatment of myasthenia gravis. pyridostigmine bromide is contraindicated in mechanical intestinal or urinary obstruction, and particular caution should be used in its administration to patients with bronchial asthma. care should be observed in the use of atropine for counteracting side effects, as discussed below.

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals ny llc - pyridostigmine bromide (unii: kvi301na53) (pyridostigmine - unii:19qm69hh21) - pyridostigmine bromide oral solution is useful in the treatment of myasthenia gravis. pyridostigmine bromide is contraindicated in mechanical intestinal or urinary obstruction, and particular caution should be used in its administration to patients with bronchial asthma. care should be observed in the use of atropine for counteracting side effects, as discussed below.

United States - English - NLM (National Library of Medicine)

ani pharmaceuticals, inc. - pyridostigmine bromide (unii: kvi301na53) (pyridostigmine - unii:19qm69hh21) - pyridostigmine bromide tablets usp are useful in the treatment of myasthenia gravis. pyridostigmine bromide tablets are contraindicated in mechanical intestinal or urinary obstruction, and particular caution should be used in its administration to patients with bronchial asthma. care should be observed in the use of atropine for counteracting side effects, as discussed below.

United States - English - NLM (National Library of Medicine)

vistapharm, llc - pyridostigmine bromide (unii: kvi301na53) (pyridostigmine - unii:19qm69hh21) - pyridostigmine bromide oral solution is contraindicated in mechanical intestinal or urinary obstruction, and particular caution should be used in its administration to patients with bronchial asthma. care should be observed in the use of atropine for counteracting side effects, as discussed below.